Status: Active

R3 Vascular

  • Status Current
  • Sector Peripheral Vascular
  • Year Invested 2020
  • HQ Mountain View, CA, United States & Munich, Germany
  • Clinical Operations Austria, Italy, Canada
  • Lead Partners Frederik Groenewegen


Related News

Bioresorbable Scaffold Technology for Treatment of Peripheral Vascular Disease

R3 has developed a novel technology platform of fully bioresorbable vascular scaffolds with a sirolimus coating for treatment of Peripheral Artery Disease (PAD). The R3 Vascular platform combines the best of both worlds of below-the-knee (BTK) therapy, designed to deliver the ‘stent-like’ support of a scaffold along with the anti-inflammatory result of sirolimus, but ‘disappearing’ over time as the vessel heals.